Clinical Trials on NSCLC

Total 1027 results

Arbeitsgemeinschaft medikamentoese Tumortherapie

Recruiting

Lung Cancer Registry

Lung Cancer | NSCLC Stage IV | NSCLC, Stage III | SCLC, Extensive Stage | SCLC, Limited Stage

Austria
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors

NSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MF

China
Maastricht Radiation Oncology
Academisch Ziekenhuis Maastricht

Terminated

Predictive Value of FDG-PET-CT Scans for Patients With Lung Cancer Receiving Concurrent Chemo-Radiation (FDG-PET lung)

NSCLC | Lung Cancer | SCLC

Netherlands
Shanghai Henlius Biotech

Completed

Study on Food Influence and Drug-drug Interaction of HLX208 Tablets in Chinese Healthy Subjects

NSCLC

China
The Netherlands Cancer Institute

Enrolling by invitation

The Food-effect on Alectinib Pharmacokinetics

NSCLC

Netherlands
Biocartis NV
AstraZeneca

Withdrawn

EGFR_IUO 3.20 Clinical Study Protocol

NSCLC
Centre Oscar Lambret
University Hospital, Lille

Terminated

Correlation Between Tissue and Plasmatic EGFR in CBNPC With EGFR Mutation or Predictive Factor of EGFR Mutation (CONCORDE)

Nsclc

France
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Completed

To Evaluate the Effect of Food on the Pharmacokinetic Characteristics of Alkotinib Capsules in Healthy Subjects

NSCLC

China
Bio-Thera Solutions

Completed

Study of Bevacizumab(BAT1706) and Comparators in Healthy Subjects

NSCLC

New Zealand
Xinqiao Hospital of Chongqing

Completed

Clinical Research for the Consistency Analysis of PD-L1 in Cancer Tissue and Plasma Exosome (RadImm01)

NSCLC
Seoul St. Mary's Hospital
Boehringer Ingelheim

Active, not recruiting

Retrospective Multi-cohort Study of Frontline Afatinib Followed by 2nd Line Therapy Including Osimertinib, Chemotherapy or Other Therapy

NSCLC

Korea, Republic of
Taipei Veterans General Hospital, Taiwan
National Taiwan University Hospital; China Medical University Hospital; Tri-Service... and other collaborators

Unknown

Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

NSCLC

Taiwan
AstraZeneca

Completed

Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study

NSCLC

Sweden, Bulgaria, Mexico, Russian Federation, Turkey, United Kingdom, Philippines, Malaysia, Germany, Hungary, Latvia, Lithuania, Poland, Romania, Netherlands, Norway, Argentina, Australia, Canada, Slovakia, Greece, Taiwan, Thailand, ... and more
Jiangsu Province Nanjing Brain Hospital

Recruiting

The Dynamic Monitoring of Cerebrospinal Fluid ctDNA

NSCLC

China
TYK Medicines, Inc

Recruiting

Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects

NSCLC

China
Radboud University Medical Center
Pfizer; ImaginAb, Inc.; University Hospital Tuebingen

Not yet recruiting

Immuno-pet iMaging resPonses administeRed Immune checkpoiNt inhibiTor (IMPRINT)

NSCLC

Germany, Netherlands
Beta Pharma, Inc.

Completed

A Phase I Study to Assess the Effect of Itraconazole and Rifampicin on Pharmacokinetics Profile of BPI-7711

NSCLC

China
Pfizer

Completed

A Rollover Protocol of Dacomitinib For Patients In Japan

NSCLC

Japan
Tianjin Medical University Cancer Institute and...
Guangzhou Burning Rock Dx Co., Ltd.; AstraZeneca Investment (China) Co., Ltd

Completed

Comprehensive Analysis of Gene Mutation Profile in Chinese NSCLC Patients by Next-generation Sequencing

NSCLC
Fondazione Policlinico Universitario Agostino Gemelli...

Completed

Alectinib-induced Endocrine Toxicity (TOSS-ALK)

NSCLC Stage IV

Italy
Spanish Lung Cancer Group

Completed

T790M Mutation Testing in Blood by Different Methodologies

NSCLC Stage IV

Spain
Betta Pharmaceuticals Co., Ltd.

Unknown

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

ALK-POSITIVE NSCLC

China
Xiaorong Dong

Unknown

The Role of Microbiota on the Development of Lung Cancer

Healthy Subjects | NSCLC Stage IV | NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage II

China
Fox Chase Cancer Center
WindMIL Therapeutics

Withdrawn

Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab

NSCLC | SCLC
University Hospital Heidelberg
Roche Pharma AG

Recruiting

Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC (iReP)

NSCLC Stage IIIB | NSCLC Stage II | NSCLC, Stage IIIA

Germany
Jair Bar, M.D., Ph.D.

Not yet recruiting

Neo-Bio-ADAURA: A Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib

Non-squamous NSCLC
The Netherlands Cancer Institute
AstraZeneca

Unknown

Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment (Induction)

Stage III NSCLC

Netherlands
Genentech, Inc.
Flatiron Health, Inc.; Foundation Medicine, Inc.

Completed

Prospective Clinicogenomic Program (PCG)

Non-Small Cell Lung Cancer (NSCLC) | Small-Cell Lung Cancer (SCLC)

United States
Shanghai Chest Hospital
The Affiliated Hospital of Qingdao University; Zhejiang University; Anhui Provincial...

Recruiting

Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) (AK104IIT018)

NSCLC Stage IV | NSCLC Stage IIIB | NSCLC Stage IIIC

China
The First Affiliated Hospital of Guangzhou Medical...

Recruiting

A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

NSCLC, Stage III | NSCLC, Stage I | NSCLC, Stage II

China
Fundación GECP

Active, not recruiting

Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients (CUBIK)

NSCLC | Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB

Spain
Jacobio Pharmaceuticals Co., Ltd.
AbbVie

Recruiting

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

NSCLC | Solid Tumor

United States
Biodesix, Inc.

Active, not recruiting

A Registry to Evaluate the Performance of the BDX-XL2 Test (ORACLE)

NSCLC | Nodule Solitary Pulmonary

United States
Peking Union Medical College

Recruiting

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB | NSCLC, Recurrent

China
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Completed

Assessing the Pharmacokinetics Effects of Food on ASK120067 in Single Oral Administration in Chinese Healthy Subjects

Locally Advanced or Metastatic NSCLC

China
EQRx, Inc.

Completed

To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic Populations

NSCLC | Healthy Volunteers | Pharmacokinetics

United States, New Zealand
Shanghai Chest Hospital

Unknown

SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations

NSCLC | SBRT | GM-CSF

China
Exelixis

Completed

Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer

Cancer | NSCLC | Solid Tumors

Japan
Rain Oncology Inc

Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN)

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong
Xuanzhu Biopharmaceutical Co., Ltd.

Not yet recruiting

A Study of XZB-0004 in Patients With Solid Tumors

NSCLC | Advanced Solid Tumor

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China

NSCLC | Solid Tumor | CRC

China
Beta Pharma, Inc.

Completed

A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711

NSCLC

China
Jun Zhang, MD, PhD
Genentech, Inc.; Exelixis

Not yet recruiting

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) (Cabatezo-1)

Lung Cancer | NSCLC Stage IV | Advanced NSCLC | Metastatic NSCLC - Non-Small Cell Lung Cancer

United States
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

NSCLC | Advanced Solid Tumor | CRC

United States
Shanghai Huaota Biopharmaceutical Co., Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

NSCLC | Advanced Solid Tumor

United States, China
Niguarda Hospital
University of Turin, Italy; Fondazione del Piemonte per l'Oncologia

Completed

Donation of Post Mortem Tumor Tissues (DONUM)

NSCLC Stage IV | CRC | CUP

Italy
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Completed

Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole

Locally Advanced or Metastatic NSCLC

China
InventisBio Co., Ltd
Merck Sharp & Dohme LLC

Active, not recruiting

Study to Evaluate D-1553 in Subjects With Solid Tumors

NSCLC | Solid Tumor, Adult | CRC

United States, Taiwan, Australia, Korea, Republic of
The University of Hong Kong

Unknown

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB

Hong Kong
Simcere Pharmaceutical Co., Ltd

Unknown

Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)

Advanced NSCLC | Recurrent NSCLC

China

Clinical Trials on NSCLC

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations